Analysts Expect Veru Inc. (NASDAQ:VERU) Will Announce Earnings of -$0.17 Per Share

Equities research analysts expect Veru Inc. (NASDAQ:VERUGet Rating) to post ($0.17) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Veru’s earnings, with estimates ranging from ($0.32) to ($0.09). Veru posted earnings per share of ($0.03) in the same quarter last year, which would indicate a negative year over year growth rate of 466.7%. The business is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Veru will report full year earnings of ($0.34) per share for the current year, with EPS estimates ranging from ($0.51) to $0.04. For the next financial year, analysts forecast that the company will post earnings of ($0.36) per share, with EPS estimates ranging from ($0.48) to ($0.09). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Veru.

Veru (NASDAQ:VERUGet Rating) last released its earnings results on Thursday, May 12th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.02). Veru had a negative return on equity of 10.62% and a negative net margin of 26.68%. During the same period in the prior year, the company earned ($0.04) EPS.

Several analysts recently weighed in on VERU shares. TheStreet upgraded Veru from a “d+” rating to a “c” rating in a report on Friday, April 29th. HC Wainwright lifted their price objective on Veru from $21.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, April 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Veru in a report on Friday. Zacks Investment Research downgraded Veru from a “buy” rating to a “hold” rating in a report on Thursday, April 21st. Finally, Jefferies Financial Group boosted their target price on shares of Veru from $33.00 to $55.00 in a report on Friday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $32.75.

Several hedge funds have recently modified their holdings of VERU. Millennium Management LLC grew its stake in shares of Veru by 407.1% during the third quarter. Millennium Management LLC now owns 543,593 shares of the company’s stock worth $4,637,000 after acquiring an additional 436,394 shares during the last quarter. Cubist Systematic Strategies LLC grew its stake in shares of Veru by 1,229.1% during the fourth quarter. Cubist Systematic Strategies LLC now owns 263,281 shares of the company’s stock worth $1,551,000 after acquiring an additional 243,472 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Veru by 193.8% during the third quarter. Goldman Sachs Group Inc. now owns 321,868 shares of the company’s stock worth $2,745,000 after acquiring an additional 212,314 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Veru during the third quarter worth about $1,491,000. Finally, BlackRock Inc. grew its stake in shares of Veru by 3.8% during the third quarter. BlackRock Inc. now owns 4,237,483 shares of the company’s stock worth $36,146,000 after acquiring an additional 154,862 shares during the last quarter. Institutional investors and hedge funds own 29.11% of the company’s stock.

Shares of VERU stock traded up $3.97 on Friday, hitting $13.00. The stock had a trading volume of 109,410,370 shares, compared to its average volume of 25,415,936. The business has a 50 day moving average price of $8.17 and a 200 day moving average price of $7.06. The company has a market cap of $1.04 billion, a PE ratio of -38.23 and a beta of -0.57. Veru has a one year low of $4.34 and a one year high of $17.50.

Veru Company Profile (Get Rating)

Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.

Featured Articles

Get a free copy of the Zacks research report on Veru (VERU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.